The laboratory of PUMCH, in collaboration with the infection department, pharmacy and department of infectious diseases, after a careful monitoring as long as 15 years, has discovered the trends of drug resistance of many important pathogens. For 15 years on end, the research team has been publishing an annual report entitled PUMCH Analysis on Pathogen Distribution and Drug Sensitivity. The practice has spread to more than a thousand hospitals and our hospital has led several multi-center drug resistance monitoring projects across the country, contributing significantly to China’s health undertakings. The research has thus won second prize of 2015 PUMCH medical achievement award.
To cope with changes in the resistance of various pathogens, the laboratory, together with other departments said above, issued annual monitoring reports. The practice was admired by brother hospitals across the country and approved of by the National Health and Family Planning Commission. The research team published 10 theses on core journals. Based on related multi-center monitoring projects, 13 SCI theses were published with a total IF of 42.888, and there were also 12 theses on core journals.
To further promote this field and spread the “PUMCH mode” to China, the team took lead in several multi-center drug resistance monitoring projects. Based on that, the team, using strain and clinical information collected, completed the clinical assessment of several new-type antifungal drugs including flomoxef and ceftaroline. Some discoveries are China unique. For instance, ceftaroline, a new kind of cephalosporins, was chiefly designed for antibiotic activity for MRSA. Though it displayed rather good activity against MRSA in international assessments, in two projects led by our hospital it showed only about 60% sensitivity with MRSA strains. Similar results were later reported by researchers in other Asia-Pacific regions, showing that this kind of new cephalosporin cannot well address MRSA infection and its treatment in China.